Navigation Links
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Date:5/17/2009

i> was present in 36% of patients in the study. 46% of the patients were over the age of 65, 56% were in-patients, 17% had a prior episode of CDI and study participants had an average of 8.3 bowel movements per day.

The incidence of adverse events and serious adverse events between the fidaxomicin and Vancocin arms was similar.

Additional detailed data from the study will be presented at medical conferences throughout the year.

Fidaxomicin Clinical Study Design

629 adult subjects were enrolled in this multi-center, randomized, double-blind Phase 3 clinical trial, which was the largest such trial for the treatment of CDI. Subjects with confirmed CDI received either 200 mg fidaxomicin dosed orally twice daily or 125 mg Vancocin dosed orally four times daily. This study was conducted in more than 100 clinical sites throughout North America. The objective of the study was to show that a 10-day course of fidaxomicin was at least as efficacious (non-inferior) and safe as a 10-day course of Vancocin (vancomycin hydrochloride capsules, USP) for the treatment of CDI.

The primary endpoint of the study was clinical cure defined as patients requiring no further CDI therapy two days after completion of study medication, as determined by the investigator. The secondary endpoint evaluated CDI recurrence up to four weeks post therapy with recurrence defined as the return of diarrhea associated with CDI confirmed by a positive toxin test. Global cure was defined as patients who were cured and did not have a recurrence.

About Clostridium Difficile Infection

CDI has become a growing problem in hospitals, long-term care facilities and in the community. It is a serious illness caused by infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe d
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... 2010 Unilife Corporation ( Unilife or ... that it has completed the A$23.1 million private placement ( Placement ... Unilife issued 27,228,143 CHESS Depositary Interests ( CDIs ) ( ... representing an interest in one sixth of a share of the ...
... InfraReDx, Inc. , a medical device company developing ... E. Muller, M.D., founder and chief executive officer, will ... Diabetes & Obesity Conference, to be held December 7-8, ... The InfraReDx presentation is scheduled to take ...
Cached Medicine Technology:Unilife Completes A$23.1 Million Private Placement 2Unilife Completes A$23.1 Million Private Placement 3Unilife Completes A$23.1 Million Private Placement 4Unilife Completes A$23.1 Million Private Placement 5
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... more procedures to reopen arteries, study found , , MONDAY, ... in the left main coronary artery, percutaneous coronary intervention ... be a viable alternative to bypass surgery. , "We ... PCI and surgery," Dr. Seung-Jung Park, senior author of ...
... N.J., March 31 The Palace was the backdrop,for ... Council,(NJTC) crowned the "Best in Show" at the 2008 ... Most Likely to Succeed" and,Switch2Health of New Brunswick took ... event drew a crowd of more than 500 entrepreneurs,and ...
... is available in French . , Montreal, March ... has identified a novel gene responsible for a significant fraction ... referred to as Lou Gehrigs disease, an incurable neuromuscular disorder ... within one to five years. , Published in the current ...
... 2, ,Kick Butts Day, at 11 a.m. in Kettering, ... youth leaders from Ohio will hold a press conference ... describes how tobacco,companies take advantage of the lack of ... products aimed at hooking kids and,preventing current smokers from ...
... New Artis zee Family Provides Interventional Cardiologists with Enhanced ... Imaging for Faster, More Precise Procedures, CHICAGO, ... ranks as America,s No. 1 killer,with an average of one ... the obesity epidemic have contributed to the surge of,Americans with ...
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... independent registered public accounting firm regarding the,Company,s ... the Company,s ability to continue as a ... to publicly announce if,their Annual Report on ...
Cached Medicine News:Health News:Angioplasty Proves Reasonable Alternative to Bypass Surgery 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 2Health News:Technology Shines at 2008 NJTC Venture Conference; 'Best in Show' Winners Announced 3Health News:Researchers identify a gene responsible for Lou Gehrig's disease 2Health News:Ohio Faith Leaders Call on Sen. Voinovich to Cosponsor Legislation to Protect Kids From Tobacco 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 2Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 3Health News:See More, Do More: Siemens Highlights New Generation of Interventional Imaging Systems for Cardiology at ACC 4Health News:Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K 2Health News:Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K 3
Shandon Stackable Slide Storage Cabinet...
Shandon Plastic Slide Boxes...
Shandon Microscope Slide Cabinet with Drawers...
... The PSL utilizes a high luminance white LED ... lightweight, compact design, to give you the freedom ... The PSL Slit Lamp weighs only about 1.5 ... easily and comfortably in your hand. Its ...
Medicine Products: